
|Articles|April 27, 2003
Treatment advances for overactive bladder 'pushing the therapeutic index'
Chicago-Some researchers investigating the physiology and treatment ofoveractive bladder have questioned whether a "therapeutic ceiling"has been reached with anticholinergic medications, the current mainstayof treatment. Although the balance between efficacy and tolerability ofanticholinergics falls short of ideal, a number of products under developmenthold promise, said Roger Dmochowski, MD, professor of urology at VanderbiltUniversity School of Medicine in Nashville, TN.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5















